{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T02:39:26Z","timestamp":1794451166782,"version":"4.9.1"},"reference-count":35,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2023,12,21]],"date-time":"2023-12-21T00:00:00Z","timestamp":1703116800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"National Research Foundation of Korea (NRF)","award":["2018R1D1A1B07049542"],"award-info":[{"award-number":["2018R1D1A1B07049542"]}]},{"name":"National Research Foundation of Korea (NRF)","award":["2019M3E5D3073104"],"award-info":[{"award-number":["2019M3E5D3073104"]}]},{"name":"National Research Foundation of Korea (NRF)","award":["2019R1A5A2027588"],"award-info":[{"award-number":["2019R1A5A2027588"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Although the intravesical instillation of Bacillus Calmette-Guerin (BCG) is widely used as adjuvant treatment for nonmuscle-invasive bladder cancers, the clinical benefit is variable across patients, and the molecular mechanisms underlying the sensitivity to BCG administration and disease progression are poorly understood. To establish the molecular signatures that predict the responsiveness and disease progression of bladder cancers treated with BCG, we performed transcriptome sequencing (RNA-seq) for 13 treatment-na\u00efve and 22 post-treatment specimens obtained from 14 bladder cancer patients. To overcome disease heterogeneity, we used non-negative matrix factorization to identify the latent molecular features associated with drug responsiveness and disease progression. At least 12 molecular features were present, among which the immune-related feature was associated with drug responsiveness, indicating that pre-treatment anti-cancer immunity might dictate BCG responsiveness. We also identified disease progression-associated molecular features indicative of elevated cellular proliferation in post-treatment specimens. The progression-associated molecular features were validated in an extended cohort of BCG-treated bladder cancers. Our study advances understanding of the molecular mechanisms of BCG activity in bladder cancers and provides clinically relevant gene markers for evaluating and monitoring patients.<\/jats:p>","DOI":"10.3390\/ijms25010144","type":"journal-article","created":{"date-parts":[[2023,12,21]],"date-time":"2023-12-21T08:16:02Z","timestamp":1703146562000},"page":"144","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Longitudinal Transcription Profiling of Bladder Cancers Dictate the Response to BCG Treatment and Disease Progression"],"prefix":"10.3390","volume":"25","author":[{"given":"Seo-Young","family":"Lee","sequence":"first","affiliation":[{"name":"Department of Medical Informatics, College of Medicine, The Catholic University of Korea, Seoul 03083, Republic of Korea"},{"name":"Cancer Research Institute, College of Medicine, The Catholic University of Korea, Seoul 03083, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9177-2553","authenticated-orcid":false,"given":"Yun-Hee","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Urology, College of Medicine, The Catholic University of Korea, Seoul 03083, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tae-Min","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Medical Informatics, College of Medicine, The Catholic University of Korea, Seoul 03083, Republic of Korea"},{"name":"Cancer Research Institute, College of Medicine, The Catholic University of Korea, Seoul 03083, Republic of Korea"},{"name":"Department of Biomedicine & Health Sciences, Graduate School, The Catholic University of Korea, Seoul 03083, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"U-Syn","family":"Ha","sequence":"additional","affiliation":[{"name":"Cancer Research Institute, College of Medicine, The Catholic University of Korea, Seoul 03083, Republic of Korea"},{"name":"Department of Urology, College of Medicine, The Catholic University of Korea, Seoul 03083, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,12,21]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1007\/s00345-019-02984-4","article-title":"The global burden of urinary bladder cancer: An update","volume":"38","author":"Richters","year":"2020","journal-title":"World J. Urol."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Saginala, K., Barsouk, A., Aluru, J.S., Rawla, P., Padala, S.A., and Barsouk, A. (2020). Epidemiology of Bladder Cancer. Med. Sci., 8.","DOI":"10.3390\/medsci8010015"},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Ferro, M., T\u0103taru, O.S., Musi, G., Lucarelli, G., Abu Farhan, A.R., Cantiello, F., Damiano, R., Hurle, R., Contieri, R., and Busetto, G.M. (2022). Modified Glasgow Prognostic Score as a Predictor of Recurrence in Patients with High Grade Non-Muscle Invasive Bladder Cancer Undergoing Intravesical Bacillus Calmette\u2013Guerin Immunotherapy. Diagnostics, 12.","DOI":"10.3390\/diagnostics12030586"},{"key":"ref_4","first-page":"43","article-title":"Non-muscle-invasive Bladder Cancer: Overview and Contemporar Treatment Landscape of Neoadjuvant Chemoablative Therapies","volume":"22","author":"Matulewicz","year":"2020","journal-title":"Rev. Urol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"490.e13","DOI":"10.1016\/j.urolonc.2022.05.016","article-title":"Predictive clinico-pathological factors to identify BCG, unresponsive patients, after re-resection for T1 high grade non-muscle invasive bladder cancer","volume":"40","author":"Ferro","year":"2022","journal-title":"Urol. Oncol."},{"key":"ref_6","first-page":"14","article-title":"Clinical practice guideline for transurethral plasmakinetic resection of prostate for benign prostatic hyperplasia (2021 Edition)","volume":"9","author":"Zeng","year":"2022","journal-title":"Mil. Med. Res."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.eururo.2016.05.041","article-title":"EAU Guidelines on Non\u2013Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016","volume":"71","author":"Babjuk","year":"2017","journal-title":"Eur. Urol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1016\/j.juro.2009.07.016","article-title":"Predicting nonmuscle invasive bladder cancer recurrence and progression in patients treated with bacillus Calmette-Guerin: The CUETO scoring model","volume":"182","author":"Madero","year":"2009","journal-title":"J. Urol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/S0022-5347(17)58737-6","article-title":"Intracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumors","volume":"116","author":"Morales","year":"1976","journal-title":"J. Urol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1002\/cncr.30392","article-title":"Non-muscle-invasive bladder cancer: Intravesical treatments beyond Bacille Calmette-Guerin","volume":"123","author":"Packiam","year":"2017","journal-title":"Cancer"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1038\/s41467-021-22465-w","article-title":"An integrated multi-omics analysis identifies prognostic molecular subtypes of non-muscle-invasive bladder cancer","volume":"12","author":"Lindskrog","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1002\/cncr.24914","article-title":"Gemcitabine versus bacille Calmette-Guerin after initial bacille Calmette-Guerin failure in non-muscle-invasive bladder cancer: A multicenter prospective randomized trial","volume":"116","author":"Damiano","year":"2010","journal-title":"Cancer"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1038\/s41585-018-0055-4","article-title":"Mechanisms of BCG immunotherapy and its outlook for bladder cancer","volume":"15","author":"Pettenati","year":"2018","journal-title":"Nat. Rev. Urol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.bbacli.2015.06.002","article-title":"Treatment of non-muscle invasive bladder cancer with Bacillus Calmette\u2013Guerin (BCG): Biological markers and simulation studies","volume":"4","author":"Kiselyov","year":"2015","journal-title":"BBA Clin."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.eururo.2019.09.006","article-title":"A Consensus Molecular Classification of Muscle-invasive Bladder Cancer","volume":"77","author":"Kamoun","year":"2020","journal-title":"Eur. Urol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.omto.2021.02.001","article-title":"Tumor immune microenvironment-based classifications of bladder cancer for enhancing the response rate of immunotherapy","volume":"20","author":"Meng","year":"2021","journal-title":"Mol. Ther. Oncolytics"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ccell.2016.05.004","article-title":"Comprehensive Transcriptional Analysis of Early-Stage Urothelial Carcinoma","volume":"30","author":"Hedegaard","year":"2016","journal-title":"Cancer Cell"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Ye, L., Chen, Y., Xu, H., Wang, Z., Li, H., Qi, J., Wang, J., Yao, J., Liu, J., and Song, B. (2022). Radiomics of Contrast-Enhanced Computed Tomography: A Potential Biomarker for Pretreatment Prediction of the Response to Bacillus Calmette-Guerin Immunotherapy in Non-Muscle-Invasive Bladder Cancer. Front. Cell Dev. Biol., 10.","DOI":"10.3389\/fcell.2022.814388"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1038\/44565","article-title":"Learning the parts of objects by non-negative matrix factorization","volume":"401","author":"Lee","year":"1999","journal-title":"Nature"},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Vidak, E., Javor\u0161ek, U., Vizovi\u0161ek, M., and Turk, B. (2019). Cysteine Cathepsins and their Extracellular Roles: Shaping the Microenvironment. Cells, 8.","DOI":"10.3390\/cells8030264"},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Yang, J., Luo, G., Li, C., Zhao, Z., Ju, S., Li, Q., Chen, Z., Ding, C., Tong, X., and Zhao, J. (2022). Cystatin SN promotes epithelial-mesenchymal transition and serves as a prognostic biomarker in lung adenocarcinoma. BMC Cancer, 22.","DOI":"10.1186\/s12885-022-09685-z"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"8790","DOI":"10.7150\/thno.44456","article-title":"Cartilage Oligomeric Matrix Protein promotes epithelial-mesenchymal transition by interacting with Transgelin in Colorectal Cancer","volume":"10","author":"Zhong","year":"2020","journal-title":"Theranostics"},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"de Koning, P.J.A., Kummer, J.A.H., de Poot, S.A., Quadir, R., Broekhuizen, R., McGettrick, A.F., Higgins, W.J., Devreese, B., Worrall, D.M., and Bovenschen, N. (2011). Intracellular serine protease inhibitor SERPINB4 inhibits granzyme M-induced cell death. PLoS ONE, 6.","DOI":"10.1371\/journal.pone.0022645"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.cellimm.2013.11.007","article-title":"BCG vaccine mediated reduction in the MHC-II expression of macrophages and dendritic cells is reversed by activation of Toll-like receptors 7 and 9","volume":"287","author":"Bakhru","year":"2014","journal-title":"Cell. Immunol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"3377","DOI":"10.1158\/1078-0432.CCR-12-0077-T","article-title":"A molecular taxonomy for urothelial carcinoma","volume":"18","author":"Lauss","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"ref_26","unstructured":"Andrews, S. (2010). FastQC: A Quality Control Tool for High Throughput Sequence Data, Babraham Bioinformatics, Babraham Institute."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"3047","DOI":"10.1093\/bioinformatics\/btw354","article-title":"MultiQC: Summarize analysis results for multiple tools and samples in a single report","volume":"32","author":"Ewels","year":"2016","journal-title":"Bioinformatics"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"i884","DOI":"10.1093\/bioinformatics\/bty560","article-title":"fastp: An ultra-fast all-in-one FASTQ preprocessor","volume":"34","author":"Chen","year":"2018","journal-title":"Bioinformatics"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","article-title":"STAR: Ultrafast universal RNA-seq aligner","volume":"29","author":"Dobin","year":"2013","journal-title":"Bioinformatics"},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Li, B., and Dewey, C.N. (2011). RSEM: Accurate transcript quantification from RNA-Seq data with or without a reference genome. BMC Bioinform., 12.","DOI":"10.1186\/1471-2105-12-323"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1080\/01621459.1951.10500769","article-title":"The Kolmogorov-Smirnov test for goodness of fit","volume":"46","author":"Massey","year":"1951","journal-title":"J. Am. Stat. Assoc."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"H\u00e4nzelmann, S., Castelo, R., and Guinney, J. (2013). GSVA: Gene set variation analysis for microarray and RNA-seq data. BMC Bioinform., 14.","DOI":"10.1186\/1471-2105-14-7"},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Becht, E., Giraldo, N.A., Lacroix, L., Buttard, B., Elarouci, N., Petitprez, F., Selves, J., Laurent-Puig, P., Saut\u00e8s-Fridman, C., and Fridman, W.H. (2016). Estimating the population abundance of tissue-infiltrating immune and stromal cell populations using gene expression. Genome Biol., 17.","DOI":"10.1186\/s13059-016-1070-5"},{"key":"ref_34","first-page":"790","article-title":"Package \u2018pheatmap\u2019","volume":"1","author":"Kolde","year":"2015","journal-title":"R Package"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"e145666","DOI":"10.1172\/JCI145666","article-title":"BCG therapy downregulates HLA-I on malignant cells to subvert antitumor immune responses in bladder cancer","volume":"132","author":"Rouanne","year":"2022","journal-title":"J. Clin. Investig."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/25\/1\/144\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T21:39:43Z","timestamp":1760132383000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/25\/1\/144"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,21]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,1]]}},"alternative-id":["ijms25010144"],"URL":"https:\/\/doi.org\/10.3390\/ijms25010144","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,21]]}}}